Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Stafilochinasi Non Immunogenica a Bolo Singolo in Pazienti con Ictus Ischemico Acuto entro 4,5-24 Ore dall'Esordio dei Sintomi (FRIDA-CT)

10 novembre 2026 aggiornato da: Supergene, LLC

Uno Studio Multicentrico, in Doppio Cieco, Randomizzato, Controllato con Placebo sull'Efficacia e la Sicurezza della Stafilochinasi Ricombinante Non-immunogena in Pazienti con Ictus Ischemico Acuto entro 4,5-24 Ore dall'Esordio dei Sintomi (FRIDA-CT)

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.

In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.

A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.

Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.

In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.

Tipo di studio

Interventistico

Iscrizione (Stimato)

1050

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Nikolay A. Shamalov, MD, prof
  • Numero di telefono: +7 (499) 936-99-37
  • Email: shamalovn@gmail.com

Backup dei contatti dello studio

Luoghi di studio

      • Chelyabinsk, Russia
        • Reclutamento
        • Chelyabinsk Regional Clinical Hospital No. 3
        • Contatto:
        • Investigatore principale:
          • Dmitry V. Popov, PhD
      • Irkutsk, Russia, 664079
        • Reclutamento
        • Irkutsk Regional Clinical Hospital
        • Contatto:
        • Investigatore principale:
          • Ivan V. Korobeynikov, PhD
      • Kazan', Russia, 420101
        • Reclutamento
        • Interregional Clinical and Diagnostic Center
        • Contatto:
        • Investigatore principale:
          • Dina R. Khasanova, MD, Prof
      • Krasnodar, Russia, 350086
        • Reclutamento
        • S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
        • Contatto:
        • Investigatore principale:
          • Ludmila V. Timchenko, MD, prof
      • Krasnogorsk, Russia, 143408
        • Reclutamento
        • Krasnogorsk Clinical Hospital
        • Contatto:
          • Svetlana V. Alexandrova
          • Numero di telefono: +7 (498) 602-03-73
          • Email: clairalex@mail.ru
        • Investigatore principale:
          • Svetlana V. Alexandrova
      • Moscow, Russia, 108814
        • Reclutamento
        • Moscow Multidisciplinary Clinical Center "Kommunarka"
        • Contatto:
        • Investigatore principale:
          • Denis N. Protsenko, PhD
      • Moscow, Russia, 117997
        • Reclutamento
        • N.I. Pirogov Russian National Research Medical University
        • Contatto:
        • Investigatore principale:
          • Larisa L. Korsunskaya, MD, Prof
      • Nizhny Novgorod, Russia, 603126
        • Non ancora reclutamento
        • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
        • Contatto:
        • Investigatore principale:
          • Valentina N. Nesterova, PhD
      • Orenburg, Russia
        • Reclutamento
        • V.I. Voynov Orenburg Regional Clinical Hospital
        • Contatto:
        • Investigatore principale:
          • Alexandr N. Chirkov, PhD
      • Saint Petersburg, Russia, 193079
        • Reclutamento
        • St. Petersburg Hospital for War Veterans
        • Contatto:
        • Investigatore principale:
          • Maria A. Privalova, PhD
      • Saint Petersburg, Russia, 194291
        • Reclutamento
        • Leningradskaya Regional Clinical Hospital
        • Contatto:
        • Investigatore principale:
          • Natalya V. Zhukovskaya, MD, prof
      • Solnechnogorsk, Russia, 141508
        • Non ancora reclutamento
        • Solnechnogorsk District Hospital
        • Investigatore principale:
          • Anton G. Koledinsky, MD, PhD
        • Contatto:
          • Anton G. Koledinsky, MD, PhD
          • Numero di telefono: +7 (496) 264-14-56
          • Email: koledant@mail.ru
      • Tver', Russia, 170036
        • Reclutamento
        • Tver Regional Clinical Hospital
        • Contatto:
          • Ksenia V. Khoroshavina
          • Numero di telefono: +7 (482) 277-54-65
          • Email: kseniarep@mail.ru
        • Investigatore principale:
          • Ksenia V. Khoroshavina
      • Ulyanovsk, Russia
        • Reclutamento
        • Ulyanovsk Regional Clinical Hospital
        • Contatto:
        • Investigatore principale:
          • Irina V. Greshnova, PhD
      • Volgograd, Russia, 400138
        • Reclutamento
        • City Clinical Hospital of Emergency Medical Care No. 25
        • Contatto:
        • Investigatore principale:
          • Eduard A. Ponomarev, MD, prof
      • Yekaterinburg, Russia, 620102
        • Reclutamento
        • Sverdlovsk Regional Clinical Hospital No. 1
        • Contatto:
        • Investigatore principale:
          • Andrey M. Alasheev, MD, prof
    • Ryazan Oblast
      • Ryazan, Ryazan Oblast, Russia, 390039
        • Non ancora reclutamento
        • Ryazan Regional Clinical Hospital
        • Contatto:
        • Investigatore principale:
          • Sergei B. Aksentyev, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Men and women aged 18 years and over;
  2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  3. Pre-stroke modified Rankin scale (mRS) score≤1;
  4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
  5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
  6. Alberta Stroke Program Early CT score (ASPECTS) > 6;
  7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
  8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
  9. Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

  1. Acute ischemic stroke within 4,5 h after symptom onset;
  2. Intended to proceed to endovascular treatment;
  3. Known hypersensitivity to the non-immunogenic staphylokinase;
  4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
  5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
  6. Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
  7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
  8. Subarachnoid hemorrhage;
  9. Major bleeding currently or within the past 6 months;
  10. Surgery on the brain or spinal cord in the last 2 months;
  11. Punctures of non-compressible arteries and veins in the last 7 days;
  12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
  13. Platelet count below 100,000/mm3;
  14. Previous stroke or severe traumatic brain injury within 3 months;
  15. Unable to perform CT or MRI;
  16. History of hemorrhagic stroke or stroke of unspecified genesis;
  17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
  18. Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
  19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
  20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
  21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
  22. Acute pancreatitis;
  23. Bacterial endocarditis, pericarditis;
  24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
  25. Cancer with an increased risk of bleeding;
  26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
  27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
  28. Hemorrhagic diathesis, including renal and hepatic failure;
  29. Data on bleeding or acute trauma (fracture) at the time of examination;
  30. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Placebo

Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization

Sperimentale: Non-immunogenic staphylokinase

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

Altri nomi:
  • Fortelyzin®

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Excellent functional outcome
Lasso di tempo: 90 days

The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days

90 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Ordinal distribution of mRS
Lasso di tempo: 90 days

Ordinal distribution of mRS at 90 days

90 days
Functional independence outcome
Lasso di tempo: 90 days

The number of patients with functional independence defined by an mRS score 0-2 point at 90 days

90 days
NIHSS change from baseline
Lasso di tempo: 7-14 days

NIHSS median change from baseline on discharge

7-14 days
The rate of improvement on reperfusion
Lasso di tempo: 24 hours

The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization.

24 hours
All-cause mortality
Lasso di tempo: 90 days

Rate of all-cause mortality within 90 days

90 days
Poor functional outcome
Lasso di tempo: 90 days

The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days

90 days

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Hemorrhagic transformation
Lasso di tempo: 24 hours

Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours

24 hours
Symptomatic intracranial hemorrhage
Lasso di tempo: 24 hours

Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours

24 hours
Major bleeding
Lasso di tempo: 90 days

Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5)

90 days
Serious adverse events (SAEs)
Lasso di tempo: 90 days

Rate of serious adverse events (SAEs) within 90 days

90 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Nikolay A. Shamalov, MD, prof, Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
  • Direttore dello studio: Sergey S. Markin, MD, prof, LLC "SuperGene"

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 giugno 2026

Completamento primario (Stimato)

1 novembre 2028

Completamento dello studio (Stimato)

1 gennaio 2029

Date di iscrizione allo studio

Primo inviato

23 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

23 dicembre 2025

Primo Inserito (Effettivo)

8 gennaio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • FRIDA-CT

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.

Periodo di condivisione IPD

within 90 days after request

Criteri di accesso alla condivisione IPD

Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .